GlobalData predicts that RPM will be the prevailing industry trend in 2021
Ongoing Covid-19 lockdowns and social distancing requirements have caused healthcare provision and patient monitoring to seek alternatives. Even though remote patient monitoring (RPM) was already being used prior to the start of the pandemic, the uptake of the technology was fairly low, mainly used to ensure better post-acute care and management of chronic conditions, such as diabetes. However, that technology is now in a position to lead to a fundamental change in healthcare services delivery and clinical trials, according to GlobalData, a data and analytics company.
GlobalData’s latest report, “The State of the Biopharmaceutical Industry 2021,” reveals that RPM is expected to become the industry trend with the most impact on the pharma industry in 2021, as confirmed by 20% of 198 pharmaceutical industry professionals.
With a growing number of patients, clinical practices and pharma companies gaining experience with RPM, the use of remote monitoring tools is expected to remain strong, even after the pandemic diminishes.